# A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.

Study · id `cardio:ct-nct06731075` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06731075](<https://clinicaltrials.gov/study/NCT06731075>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06731075

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 300 participants.

## Technical summary

Registry record NCT06731075. Randomized; quadruple masking; primary purpose treatment. Start 2025-12-15 (anticipated); primary completion 2027-04-25 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 300 participants (planned count; ClinicalTrials.gov record NCT06731075, source copy `cardio:ctgov-nct06731075-2025-08-03`, retrieved 2026-10-26)
- Planned start: 2025-12-15 (anticipated) (ClinicalTrials.gov record NCT06731075, source copy `cardio:ctgov-nct06731075-2025-08-03`, retrieved 2026-10-26)
- Primary completion: 2027-04-25 (anticipated) (ClinicalTrials.gov record NCT06731075, source copy `cardio:ctgov-nct06731075-2025-08-03`, retrieved 2026-10-26)
- Completion: 2027-05-22 (anticipated) (ClinicalTrials.gov record NCT06731075, source copy `cardio:ctgov-nct06731075-2025-08-03`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06731075, source copy `cardio:ctgov-nct06731075-2025-08-03`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06731075-2025-08-03`, retrieved 2026-10-26)

## The registry's words

- Brief title: A Phase 3 Study to Evaluate the Efficacy and Safety of ORMD-0801 in Subjects With Type 2 Diabetes Mellitus.
- Condition: Type 2 Diabetes Mellitus
- Intervention (Drug): ORMD-0801 8 mg
- Intervention (Other): Placebo capsule
- Intervention (Drug): ORMD-0801 16 mg
- Lead sponsor: Oramed, Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: InClin, Inc.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Oramed, Ltd. (`cardio:org-oramed-ltd`)

## Provenance

Content hash: 63264bc09ed00ac2c479358b168131ae40338c9e5b09061a5714c24676285dcc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
